CHRISTIEN OLEWNICZAK: Open Payments
NPI 1609498658 · LANCASTER, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,318 in 166 payments from 19 companies in 2025. Trend: 2023 $2,936 · 2024 $3,582 · 2025 $4,318
Food & beverage: $4,315Education: $4
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 33 | $868 |
| Vanda Pharmaceuticals Inc. | 20 | $654 |
| Teva Pharmaceuticals USA, Inc. | 32 | $606 |
| ABBVIE INC. | 32 | $386 |
| Otsuka America Pharmaceutical, Inc. | 11 | $379 |
| Alkermes, Inc. | 7 | $298 |
| AstraZeneca Pharmaceuticals LP | 6 | $249 |
| Axsome Therapeutics, Inc. | 4 | $174 |
| Luye Pharma (USA) Ltd. | 6 | $162 |
| E.R. Squibb & Sons, L.L.C. | 1 | $125 |
Products named: CAPLYTA, FANAPT, AUSTEDO XR, VRAYLAR, REXULTI, FARXIGA, Auvelity, ARISTADA.
Industry payments across NY — which companies pay providers there.
